Newsroom | 68363 results

CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers, and retailers of cannabis products in the United States, today announced that the ad hoc group of noteholders of the Company’s 9.25% Senior Secured Notes due December 31, 2028 and the 9.00% Senior Secured Convertible Notes due December 31, 2028 (collectively, the “Notes”), which are parties to t...

BEIJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to th...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure to Participate in 2026 Leerink Global Healthcare Conference...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of Februar...

SAN DIEGO--(BUSINESS WIRE)--RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recovering more of the revenue they earn. RevPay connects payments directly to RevolutionEHR’s AI-native platform, integrating checkout, patient records, engagement, and reporting into one intelligent workflow. By embedding payments into the platform’s intelligence engin...

MOUNT LAUREL, N.J.--(BUSINESS WIRE)--CFG Health today announced the launch of CFG CareLink™, a proprietary, in-house telehealth platform that represents the next evolution of the company’s long-standing leadership in technology-enabled correctional healthcare. CFG Health pioneered the use of telehealth in correctional settings more than two decades ago, and CareLink builds on that foundation—combining modern tablet technology, secure virtual care infrastructure, and clinically governed workflow...

PLAINVIEW, N.Y.--(BUSINESS WIRE)--Three pathology and healthcare technology leaders today announced a partnership that has resulted in the installation of the first LH510 Digital Pathology scanner in the United States, marking a significant milestone in the advancement of digital pathology and diagnostic innovation. This landmark installation represents an important step forward in expanding access to high-quality digital pathology solutions in the U.S. Through close collaboration, the partners...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer rega...

SAINT PAUL, Minn.--(BUSINESS WIRE)--The Emily Program announced a free public webinar, Up Close with Jessie Diggins, who speaks openly about her recovery from an eating disorder....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will...